NL-OMON46762
Withdrawn
Not Applicable
Clinical pilot study to determine the feasibility of detecting pancreatic beta cells using Exendin-4-800CW targeting the glucagon-like peptide 1 receptor for future application of molecular fluorescence guided surgery in insulinoma patients (BETA-light) - Detecting beta cells with a fluorescent tracer (BETA-light)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversitair Medisch Centrum Groningen
- Enrollment
- 11
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age equal to or older than 18 years;\- Patients who are scheduled to undergo a pancreatectomy due to an insulinoma, another type of neuro\-endocrine tumour or because of a suspected carcinoma.;\- WHO performance score 0\-2;\- Signed informed consent
Exclusion Criteria
- •\- Breast feeding;\- Pregnancy or the wish to become pregnant within 6 months;\- Calculated creatinine clearance below 40ml/min;\- Evidence of other malignancy in conventional imaging (suspicious liver, bone and lung lesions);\- No informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Clinical trial to determine the feasibility and safety of MSV cryopreserved in the treatment of gonartrosisEUCTR2012-004441-32-ESFundación Teknon
Completed
Not Applicable
Pilot study to assess the feasibility and patient numbers required prior to a randomised controlled trial of the effect of visual distraction for painful procedures in the burns unitISRCTN69643568Department of Health10
Recruiting
Not Applicable
To verify the feasibility and effectiveness of a distance Rehabilitation Program in the treatment of patients with Parkinson's DiseaseRBR-6sz837sBruno Lopes dos Santos Lobato
Active, not recruiting
Phase 1
A first-in-human clinical study to assess feasibility, safety and antitumor activity of genetically modified T-cells in multiple myelomaEUCTR2019-001264-30-ESniversitätsklinikum Würzburg38
Active, not recruiting
Phase 1
A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myelomaMultiple myeloma (MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2019-001264-30-ITniversitätsklinikum Würzburg38